Investigation Launched into BioAge Labs Amid Allegations of Securities Violations

NEW YORK, Dec. 28, 2024 (GLOBE NEWSWIRE) -- Renowned law firm Bleichmar Fonti & Auld LLP has initiated an investigation into BioAge Labs, Inc. (NASDAQ: BIOA) over potential breaches of federal securities laws.

If you are an investor in BioAge Labs, it is recommended that you seek further details by visiting this link.

Overview of BioAge Labs

BioAge Labs, Inc. focuses on developing treatment options for metabolic ailments, particularly obesity. Their leading product, azelaprag, is an orally administered small-molecule that targets the apelin receptor, aiming to improve weight loss outcomes.

Prior to recent events, BioAge Labs claimed that azelaprag was safely tolerated by 265 subjects in eight separate Phase 1 clinical trials. Following their initial public offering (IPO), they expressed confidence in advancing their clinical development plans.

Concerns Arise as Findings Emerge

On December 6, 2024, BioAge announced the halting of its STRIDES Phase 2 trial due to significant safety worries connected to azelaprag. The company reported cases of liver transaminitis in participants taking the medication. They indicated that this decision was made after observing the negative safety profile from the doses evaluated.

This troubling update led to a dramatic decline in the share price of BioAge, which fell over 76% from $20.09 per share on December 6, 2024, to $4.65 per share by December 9, 2024.

Where Can Investors Get Help?

If you have invested in BioAge Labs, there may be legal recourse available to you. It is advisable to submit your information to the legal firm leading the investigation.

All legal representation is provided on a contingency basis, meaning there will be no upfront costs for clients. Shareholders will not be liable for court expenses or litigation costs, as the firm will seek approval for any potential fees from the court.

To submit your information, please visit this website.

About Bleichmar Fonti & Auld LLP

Bleichmar Fonti & Auld LLP is a prominent international law firm that specializes in representing plaintiffs in securities class actions and shareholder litigation. In 2023, it was recognized as one of the top five plaintiff law firms by ISS SCAS. Attorneys at this firm have garnered prestigious accolades such as Titans of the Plaintiffs' Bar from Law360 and SuperLawyers by Thomson Reuters. Among its recent achievements, the firm has recovered over $900 million from Tesla, Inc.’s Board of Directors (pending court approval) and $420 million from Teva Pharmaceutical Industries Ltd.

For further information regarding BFA and its attorneys, visit this page.

Attorney advertising. Past results do not guarantee future outcomes.

BioAge, Investigation, Lawsuit